title: Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
authors.affiliation: a Division of Hematology , Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
authors.forename: Satoko
authors.initials: S
authors.lastname: Oka
authors.affiliation: b Division of Pathology , Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Ono
authors.affiliation: a Division of Hematology , Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
authors.forename: Masaharu
authors.initials: M
authors.lastname: Nohgawa
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D002869:Chromosome Aberrations / Q000139:chemically induced*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D000077269:Lenalidomide / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide